Home / Methylphenidate / United States
US ATC N06BA04 · updated 2 Nov 2026
Methylphenidate shortage in United States
Is there a Methylphenidate shortage in United States?
Yes. As of 2 Nov 2026, 34 Methylphenidate products are reported short in United States, the first since 26 Jul 2023. No return date has been given. Main reason: not stated.
Also short in Canada, France, Belgium, Norway, Sweden, Japan, New Zealand, Australia. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) | Janssen Pharmaceuticals | 26 Jul 2023 | not given | Not stated |
| US | Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) | Janssen Pharmaceuticals | 26 Jul 2023 | not given | Not stated |
| US | Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) | Janssen Pharmaceuticals | 26 Jul 2023 | not given | Not stated |
| US | Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) | Janssen Pharmaceuticals | 26 Jul 2023 | not given | Not stated |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01) | Teva Pharmaceuticals USA, Inc. | 26 Jul 2023 | not given | Not stated |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37) | Lannett Company, Inc. | 26 Jul 2023 | not given | Not stated |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01) limited | Teva Pharmaceuticals USA, Inc. | 26 Jul 2023 | not given | Other |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37) | Lannett Company, Inc. | 26 Jul 2023 | not given | Other |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01) limited | Teva Pharmaceuticals USA, Inc. | 26 Jul 2023 | not given | Other |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37) | Lannett Company, Inc. | 26 Jul 2023 | not given | Other |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01) | Teva Pharmaceuticals USA, Inc. | 26 Jul 2023 | not given | Not stated |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37) | Lannett Company, Inc. | 26 Jul 2023 | not given | Not stated |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) limited | Trigen Laboratories, LLC | 26 Jul 2023 | not given | Increased demand Demand increase for the drug |
| US | Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) | Vertical Pharmaceuticals, LLC | 26 Jul 2023 | not given | Not stated |
| US | Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65) | Noven Pharmaceuticals, Inc. | 28 Feb 2025 | not given | Not stated |
| US | Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65) | Noven Pharmaceuticals, Inc. | 28 Feb 2025 | not given | Not stated |
| US | Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65) | Noven Pharmaceuticals, Inc. | 28 Feb 2025 | not given | Not stated |
| US | Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65) | Noven Pharmaceuticals, Inc. | 28 Feb 2025 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).